Guggenheim Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has reaffirmed a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and increased the price target from $16 to $32, potentially indicating a positive outlook on the company's future performance.
January 02, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Longboard Pharmaceuticals and raises the price target from $16 to $32, suggesting confidence in the company's growth prospects.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future earnings and performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100